Breaking News Instant updates and real-time market news.

TSLA

Tesla

$204.03

3.33 (1.66%)

, DB

Deutsche Bank

$13.09

1.61 (14.02%)

21:44
10/02/16
10/02
21:44
10/02/16
21:44

On The Fly: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Tesla (TSLA) gave its quarterly update on global vehicle shipments, reporting a 70% rise in Q3 deliveries alongside a 37% growth in production, leading it to reaffirm its outlook for 50,000 deliveries in the second half of 2016. The numbers, which beat many analyst estimates, come at a critical time for the carmaker as it looks to reassure investors about its challenging targets for the upcoming Model 3 vehicle. 2. Deutsche Bank (DB) generated another round of headlines over the weekend, with the Wall Street Journal reporting that talks with the DOJ are continuing but have yet to produce a workable agreement, and Germany's economy minister telling reporters he's "worried" about the lender's employees. 3. Twitter (TWTR) jumped in after-hours trading Friday after Bloomberg reported that Google (GOOG) has hired an investment bank to explore a potential bid for the company. 4. The annual meeting of the European dermatology and venereology academy brought new clinical data from several drugmakers, including Novartis (NVS), Johnson & Johnson (JNJ), Regeneron (REGN) and Dermira (DERM). 5. Broadcom (AVGO), AMC Entertainment (AMC), CBS (CBS) as well as Liberty Media (LMCA) and other elements of John Malone's media empire were discussed positively in Barron's.

TSLA

Tesla

$204.03

3.33 (1.66%)

DB

Deutsche Bank

$13.09

1.61 (14.02%)

TWTR

Twitter

$23.05

0.04 (0.17%)

GOOG

Alphabet

$777.29

2.28 (0.29%)

GOOGL

Alphabet Class A

$804.06

1.42 (0.18%)

NVS

Novartis

$78.96

-0.29 (-0.37%)

JNJ

Johnson & Johnson

$118.13

0.86 (0.73%)

REGN

Regeneron

$402.02

-4.34 (-1.07%)

DERM

Dermira

$33.82

1.15 (3.52%)

AVGO

Broadcom

$172.52

0.06 (0.03%)

AMC

AMC Entertainment

$31.09

0.29 (0.94%)

CBS

CBS

$54.74

0.17 (0.31%)

LMCA

Liberty Media

$28.65

-0.07 (-0.24%)

  • 07

    Oct

  • 18

    Oct

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

  • 06

    Nov

  • 15

    Jan

  • 29

    Mar

TSLA Tesla
$204.03

3.33 (1.66%)

09/28/16
BARD
09/28/16
NO CHANGE
Target $338
BARD
Outperform
Baird estimates Tesla to report 21,000 deliveries for Q3
Baird analyst Ben Kallo said he expects Tesla (TSLA) to report its Q3 delivery figures by early next week, possibly on Monday, October 3, and he estimates the company will report 21,000 total deliveries, including 12,000 Model S deliveries and 9,000 Model X deliveries. Kallo thinks a delivery number above 20,000 vehicles will be viewed as positive and believes "shorts may return" to Tesla after the delivery announcement as the company's acquisition of SolarCity (SCTY)progresses. The analyst keeps an Outperform rating and $338 price target on Tesla shares.
09/28/16
PACS
09/28/16
NO CHANGE
PACS
Outlook mixed for Tesla, says Pacific Crest
After conducting checks, Pacific Crest analyst Brad Erickson says that orders for Tesla's Model X have improved, and he expects the company's Q3 deliveries to be "solid." However, he believes that the company is offering "aggressive" discounts on Model 3 vehicles, and he thinks the company "faces overall ASP and margin risk," along with a questionable long-term demand outlook. Erickson remains cautious on the stock and keeps a Sector Weight rating on the shares.
09/26/16
BARD
09/26/16
NO CHANGE
Target $25
BARD
Neutral
SolarCity deal spread offers short-term trading opportunity, says Baird
Baird analyst Ben Kallo noted the "substantial" spread between SolarCity's (SCTY) share price and Tesla's (TSLA) acquisition price and sees it as a short-term trading opportunity as he is increasingly confident that their deal will close, pinning an 80% probability on the chance that the merger occurs. Kallo keeps a Neutral rating and $25 price target on SolarCity shares.
09/23/16
UBSW
09/23/16
NO CHANGE
Target $160
UBSW
Sell
Tesla not a preferred car in high income homes, says UBS
UBS analyst Colin Langan said his survey of high income households shows they prefer other luxury car makers over Tesla. The results showed there is stiff competition with other brands causing Langan to remain cautious on Tesla. Langan reiterated his Sell rating and $160 price target on Tesla shares.
DB Deutsche Bank
$13.09

1.61 (14.02%)

09/29/16
COWN
09/29/16
NO CHANGE
COWN
DoJ will not destabilize Deutsche Bank, says Cowen
Cowen analyst Jaret Seiberg sees little practical or political upside for the Justice Department to press Deutsche Bank for a penalty that is so large it could destabilize the bank and create a new financial crisis. He expects the penalty for violations related to mortgage-backed securities to be structured below the speculated $14B that seems to have alarmed the market. Seiberg adds both sides have incentives to reach a deal quickly.
09/19/16
09/19/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DSW (DSW) initiated with a Negative at Susquehanna. 2. Deutsche Bank (DB) initiated with an Underperform at Credit Suisse. 3. UBS (UBS) initiated with a Neutral at Credit Suisse. 4. Cerner (CERN) initiated with a Neutral at BofA/Merrill. 5. Callidus Software (CALD) reinstated with an Outperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/16
09/30/16
NO CHANGE

Correction: Deutsche Bank credit upgraded to Neutral at BofA/Merrill
BofA/Merrill upgraded Deutsche Bank's credit to Neutral, not the equity.
09/19/16
FBCO
09/19/16
INITIATION
FBCO
Underperform
Deutsche Bank initiated with an Underperform at Credit Suisse
Credit Suisse analyst Jon Peace initiated Deutsche Bank with an Underperform saying the recent slow filing and capital shortfall will lower dividend expectations and keep shares under pressure.
TWTR Twitter
$23.05

0.04 (0.17%)

09/28/16
MZHO
09/28/16
DOWNGRADE
Target $15
MZHO
Underperform
Mizuho cuts Twitter to Underperform with $15 price target
Mizuho analyst Neil Doshi downgraded Twitter to Underperform from Neutral based on valuation. The shares are up 45% since the company reported Q2 results, primarily driven by potential buyout comments in media reports, Doshi tells investors in a research note. The stock at current levels is overvalued as Twitter's business fundamentals "have deteriorated significantly" over the past 12 months, the analyst contends. Doshi believes many of the M&A scenarios are unlikely to play out. He puts potential acquirers Salesforce (CRM) and Alphabet (GOOG, GOOGL) in the "maybe" camp, but he still has some reservations about these deals happening. The analyst believes investors of both companies would view a buyout of Twitter as negative. Doshi keeps a $15 price target for Twitter shares. The stock closed yesterday up 35c to $23.72. Loop Capital this morning also downgraded Twitter to Sell.
09/28/16
SBSH
09/28/16
NO CHANGE
SBSH
Buy
Citi hopes Disney does not acquire Twitter
Citi analyst Jason Bazinet lays out four reasons for why he doesn't like Disney (DIS) pursuing an acquisition of Twitter (TWTR). Going back 15 years, the analyst can't think of a single web-based property that was successfully acquired by a traditional media firm. Two, he calls Twitter trends "troubling." Three, Bazinet estimates a cash offer would lower Disney's stock by $5 per share while an equity offer would drop its stock by $9. Four, the analyst feels it is unclear how Disney's content will help Twitter. Bazinet thinks both Yahoo (YHOO) and Twitter lost "significant money" when they streamed NFL content over the web. The analyst hopes Twitter is acquired by somebody other than Disney. He keeps a Buy rating on Disney shares. Both Loop Capital and Mizuho this morning downgraded Twitter to sell ratings.
09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/16
LOOP
09/28/16
DOWNGRADE
Target $18
LOOP
Sell
Twitter downgraded to Sell from Hold at Loop Capital
Loop Capital analyst Blake Harper downgraded Twitter to Sell from Hold, as he believes that while the company may eventually get a takeover bid that any offer is unlikely to offer a meaningful premium from the stock's current price. The "swift manner" in which Twitter began shopping itself could be a warning sign that another disappointing earnings report is coming and there is more downside risk than upside potential if a deal falls through, said Harper, who keeps an $18 price target on Twitter shares.
GOOG Alphabet
$777.29

2.28 (0.29%)

09/27/16
WEDB
09/27/16
DOWNGRADE
WEDB
Underperform
Alphabet downgraded to Underperform from Neutral at Wedbush
Wedbush analyst James Dix downgraded Alphabet to Underperform and lowered his price target on shares to $700 on concerns the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive.
09/27/16
WEDB
09/27/16
DOWNGRADE
WEDB
Underperform
Alphabet downgraded to Underperform from Neutral at Wedbush
GOOGL Alphabet Class A
$804.06

1.42 (0.18%)

09/30/16
RBCM
09/30/16
NO CHANGE
RBCM
Street underestimating Google growth outlook, says RBC Capital
RBC Capital analyst Mark Mahaney expects Google to end 2016 with "up to 20% growth," versus the Street's outlook of mid teen percentage level growth. Mahaney says that Google's growth should be boosted by "ongoing Search innovations, rising Mobile CPCs, and the growing impact of YouTube, Play & Cloud." He thinks that YouTube's revenue is growing at a 30%-40% clip. Mahaney raised his price target on the stock to $1,025 from $1,000 and keeps an Outperform rating on the shares.
NVS Novartis
$78.96

-0.29 (-0.37%)

09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
08/31/16
LEER
08/31/16
NO CHANGE
Target $61
LEER
Outperform
Teva price target lowered to $61 from $66 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva (TEVA) to $61 from $66 on loss of Copaxone patent challenge as an upside catalyst. The analyst believes Teva's share price implies a generic entrant sometime in the second half of 2017 after losing an Inter Partes Review decision on two Copaxone 40mg anchor patents. In order to mitigate EPS downside in 2017-2018 and eliminate business uncertainty, Gerberry thinks the company should settle its Copaxone patent dispute with Novartis (NVS) and Momenta (MNTA), which he sees as "the most credible" generic threat. The analyst reiterates an Outperform rating on Teva's shares.
09/20/16
CHDN
09/20/16
INITIATION
Target $95
CHDN
Buy
Novartis initiated with a Buy at Chardan
Chardan initiated Novartis with a Buy and a $95 price target.
JNJ Johnson & Johnson
$118.13

0.86 (0.73%)

08/24/16
JEFF
08/24/16
NO CHANGE
Target $210
JEFF
Buy
Cooper Companies estimates raised at Jefferies after doctor survey
Jefferies analyst Anthony Petrone reports that the firm's survey of 52 new optometry practices suggest continued gains in dailies and stable share in monthlies for Cooper Companies (COO) and that Johnson & Johnson's (JNJ) Acuvue Vita is off to slow start. Based on the survey results, and a "significant" foreign exchange tailwind, Petrone raised his estimates for Cooper and increased his price target on the shares to $210 from $190. The firm has a Buy rating on Cooper shares.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
09/19/16
LEER
09/19/16
NO CHANGE
LEER
Abbott, Johnson & Johnson transaction positive for both companies, says Leerink
Leerink analyst Danielle Antalffy says the sale of Abbott's (ABT) Medical Optics ophthalmology business to Johnson & Johnson (JNJ) is positive for both companies. The deal strengthens Abbott's balance sheet and eliminates the need for a previously expected $3B capital raise, and adds a key component to Johnson & Johnson's already-strong vision care franchise, the analyst notes.
08/18/16
UBSW
08/18/16
NO CHANGE
Target $137
UBSW
Buy
Johnson & Johnson remains a top large cap pick, says UBS
UBS analyst Matt Miksic said Johnson & Johnson remains a top large cap diversified pick for the year. The analyst said yesterday's court ruling that invalidated the company's Remicade patent was expected and could delay the Q4 biosimilar launch but its robust pharma pipeline remains under-appreciated and should make up the difference. He said he continues to see further clarity regarding potential U.S. biosimilar competition for Remicade as positive for the stock. Miksic reiterated his Buy rating and $137 price target on Johnson & Johnson shares.
REGN Regeneron
$402.02

-4.34 (-1.07%)

09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
08/05/16
BARD
08/05/16
DOWNGRADE
Target $448
BARD
Neutral
Regeneron downgraded to Neutral at Baird
As reported previously, Baird downgraded Regeneron to Neutral from Outperform. The firm sees risk that the company will not be able to beat earnings consensus over the 2017/18 time frame unless there is a 15-20% downward revision in consensus estimates. Baird lowered its price target to $448 from $505 on Regeneron shares.
08/05/16
LEER
08/05/16
NO CHANGE
Target $511
LEER
Outperform
Regeneron price target lowered to $511 from $530 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Regeneron to $511 from $530, citing cautious guidance following the company's Q2 results. Nonetheless, the analyst points out its Eylea "solid" sales, beating by 2% in the U.S. and 5% overall. The analyst remains positive about Regeneron's product portfolio, strategy, management, and long-term potential. He reiterates an Outperform rating on the shares.
09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.
DERM Dermira
$33.82

1.15 (3.52%)

06/02/16
LEER
06/02/16
NO CHANGE
Target $47
LEER
Outperform
Dermira DRM04 results 'broadly positive,' says Leerink
Following top-line data from the two Phase 3 studies of Dermira's DRM04 for the treatment of hyperhidrosis, Leerink analyst Seamus Fernandez is raising his overall probability of success from 75% to 85%. The analyst sees the new data as "broadly positive," and notes that Dermira remains one of his Small-/Mid-Cap Top-Picks for 2016. Fernandez reiterates an Outperform rating on the stock and raised his price target on the shares to $47 from $46.
05/10/16
LEER
05/10/16
NO CHANGE
Target $46
LEER
Outperform
Dermira price target raised to $46 from $39 at Leerink
Leerink analyst Seamus Fernandez raised his price target for Dermira to $46 after upping his probability-of-success for DRM01, a topical sebum inhibitor for acne, to 90% from 75%. Top-line data showed "strongly positive" Phase IIb dose-ranging efficacy and safety, Fernandez tells investors in a post-earnings research note. He points out Dermira plans to advance DRM01 into Phase III in the first half of 2017. The analyst keeps an Outperform rating on the shares.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
05/10/16
LEER
05/10/16
NO CHANGE
Target $46
LEER
Outperform
Dermira price target raised to $46 from $39 at Leerink
AVGO Broadcom
$172.52

0.06 (0.03%)

09/29/16
EVER
09/29/16
NO CHANGE
EVER
Broadcom may also be in hunt for NXP Semiconductors, says Evercore ISI
Evercore ISI believes the report that Qualcomm (QCOM) is in talks to acquire NXP Semiconductors (NXPI) is real. The firm's analyst said a deal would most likely be done with cash, resulting in double-digit accretion for Qualcomm. The firm also sees limited antitrust concerns if Qualcomm pursues a deal to buy NXP Semi. Evercore added Broadcom (AVGO) may throw its hat in the ring and bid for NXP and said a good starting point is 14-15x on $8 earnings for a price of $116 per share.
09/20/16
SUSQ
09/20/16
INITIATION
Target $200
SUSQ
Positive
Broadcom initiated with a Positive at Susquehanna
Susquehanna analyst Christopher Rolland initiated Broadcom with a Positive and a $200 price target. The analyst is positive on the FBAR franchise and said the Broadcom segment positions in merchant networking silicon and set-top boxes should help drive increasing profitability.
09/19/16
KEYB
09/19/16
NO CHANGE
KEYB
Broadcom, Skyworks, Cirrus Logic have iPhone content gains, says KeyBanc
KeyBanc says that reports on iPhone teardowns indicate that Broadcom's (AVGO) iPhone content rose 25%-30%, while Skyworks' (SWKS) content rose 15%-20% and Cirrus' (CRUS) jumped 70%. The firm keeps an Overweight rating on Broadcom, and Sector Weight ratings on Skyworks and Cirrus.
09/30/16
COWN
09/30/16
NO CHANGE
Target $74
COWN
Outperform
Qualcomm price target raised to $74 on NXP deal potential at Cowen
Cowen analyst Timothy Arcuri noted that he has been writing about a potential Qualcomm (QCOM) acquisition of NXP Semiconductors (NXPI) for about 12 months and "would love to see it consummated" following reports that the companies are in talks. The analyst, who thinks a deal for NXP at a price of $115 paid for with a mix of cash and debt could be accretive to Qualcomm by more than 20%, raised his price target on Qualcomm shares to $74 from $62. Arcuri noted that Broadcom (AVGO) could be another potential NXP suitor, but he believes that a deal to buy Xilinx (XLNX) "makes much more sense" for Broadcom.
AMC AMC Entertainment
$31.09

0.29 (0.94%)

07/14/16
WEDB
07/14/16
NO CHANGE
WEDB
AMC Entertainment acquisition positive, says Wedbush
After AMC acquired Odeon & UCI, Wedbush expects the deal to be "mildly accretive" in 2017, before providing significant EBITDA growth in 2018. The firm thinks the company's efforts to improve its digital loyalty program will enable it to gain market share. Wedbush keeps a $33 price target and Outperform rating on AMC.
07/12/16
PIPR
07/12/16
NO CHANGE
Target $35
PIPR
Overweight
AMC acquisition puts Carmike deal at risk, says Piper Jaffray
Piper Jaffray analyst Stan Meyers believes AMC Entertainment's (AMC) acquisition of Europe's largest theater chain Odeon puts its deal with Carmike Cinemas (CKEC) at risk. The pressure on AMC to complete the Carmike deal in 2016 is "largely off the table, increasing the risk of the deal falling apart by the end of the week," Meyers tells investors in a research note. AMC management seems willing to raise its bid and potentially throw in some equity, though not to the levels expected by the Carmike key stakeholders, the analyst contends. He thinks Odeon should accelerate AMC's EBITDA growth over time. Further, the AMC/Odeon deal should also accelerate IMAX's (IMAX) expansion in Europe, Meyers contends.
08/23/16
LOOP
08/23/16
INITIATION
Target $35
LOOP
Buy
AMC Entertainment initiated with a Buy at Loop Capital
Loop Capital analyst David Miller initiated AMC Entertainment with a Buy rating and $35 price target.
08/24/16
08/24/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lockheed Martin (LMT) reinstated with a Neutral at Goldman. 2. Five Below (FIVE) initiated with a Neutral at BTIG. 3. AMC Entertainment (AMC) and Cinemark (CNK) were initiated with a Buy at Loop Capital while the firm initiated Regal Entertainment (RGC) with a Hold. 4. Delta Air Lines (DAL) initiated with an In-Line at Imperial Capital. 5. LINE Corp. (LN) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, Reference Link
CBS CBS
$54.74

0.17 (0.31%)

09/22/16
TLSY
09/22/16
DOWNGRADE
TLSY
Market Perform
CBS downgraded on likely Viacom merger at Telsey Advisory
As noted earlier, Telsey downgraded CBS (CBS) to Market Perform from Outperform. Analyst Tom Eagan says that CBS will probably merge with Viacom (VIA, VIAB). The analyst believes that it will take "years" for Viacom to be turned around, and he says that Viacom's fiscal 2017 EBITDA will come in 18% below its fiscal 2015 level. The analyst expects the company's credit rating to be downgraded by S&P. CBS target to $57 from $67.
09/20/16
WELS
09/20/16
NO CHANGE
WELS
Viacom dividend likely to be eliminated, says Wells Fargo
Wells Fargo says that the market is expecting Viacom (VIA,VIAB) to cut its dividend by 50%. However, Wells Fargo says that the company will eliminate its entire dividend within tow months from now. The firm says that a 50% cut would enable Viacom to barely make its debt payments for the next year but still leave it "with limited financial visibility running at break-even with no cushion." The firm thinks that the company needs at least some cash cushion. It does not expect the company to merge with CBS (CBS) and keeps an Underperform rating on Viacom.
09/22/16
09/22/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CBS (CBS) downgraded to Market Perform from Outperform at Telsey Advisory with analyst Tom Eagan saying that CBS will probably merge with Viacom (VIA, VIAB). 2. Jabil Circuit (JBL) downgraded to Hold from Buy at Needham with analyst Sean Hannan saying that 2017 will unlikely be a "robust year." 3. Pearson (PSO) downgraded to Neutral from Outperform at Exane BNP Paribas. 4. Syntel (SYNT) downgraded to Market Perform from Outperform at Barrington with analyst Vincent Colicchio saying he's "increasingly concerned that the challenging environment will continue to negatively impact the company's business." 5. FMC Technologies (FTI) downgraded to Neutral from Accumulate at Seaport Global wit analyst Mark Brown saying upstream customers have "little appetite" for deepwater development spending. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/22/16
TLSY
09/22/16
DOWNGRADE
TLSY
Market Perform
CBS downgraded to Market Perform from Outperform at Telsey Advisory
LMCA Liberty Media
$28.65

-0.07 (-0.24%)

07/21/16
PIPR
07/21/16
NO CHANGE
PIPR
Overweight
Pandora has several 'hidden synergies' to offer Sirius XM, says Piper Jaffray
After The Wall Street Journal reported that Sirius XM's (SIRI) controlling shareholder, Liberty Media (LMCA), previously was rejected after making a takeover overture to Pandora (P), Piper Jaffray analyst Stan Meyers laid out a "number of hidden synergies" Pandora could bring to SiriusXM, such as consumer data, an advertising sales force and the potential to combine their services into a bundle that would be "more valuable/stickier with subscribers." The analyst, who keeps an Overweight rating on Pandora, says he has "increased optimism" on the shares given the potential takeout and a number of other positives he sees.
09/13/16
SBSH
09/13/16
UPGRADE
Target $32
SBSH
Buy
Liberty Media upgraded to Buy from Neutral at Citi
Citi analyst Jason Bazinet upgraded Liberty Media Group to Buy saying the Formula One acquisition is transformative. The analyst likes the deal and believes it was done at an attractive valuation for F1. He upped his price target for Liberty Media shares to $32 from $22.
09/09/16
PACS
09/09/16
NO CHANGE
PACS
Formula One deal 'a reasonable valuation proxy' for WWE, says Pacific Crest
After Liberty Media (LMCA) agreed to buy Formula One for $8B, Pacific Crest analysts Evan Wingren and Andy Hargreaves say that Formula One was acquired for about 4.4 times EV/sales and about 17 times its LTM EV/EBITDA. They says that WWE trades at about 15 times EV/EBITDA and about two times EV/Sales, while WWWE's revenue growth and EBTIDA growth are significantly faster than those of Formula One. The analysts keeps a $24 price target and Overweight rating on WWE.
09/26/16
WDLK
09/26/16
DOWNGRADE
Target $31
WDLK
Hold
Liberty Media downgraded to Hold from Buy at Wunderlich
Wunderlich analyst Matt Harrigan downgraded Liberty Media Group to Hold citing valuation. The analyst believes the shares at current levels reflect the growth from the F1 acquisition. Harrigan raised his price target for the Liberty Media shares to $31.

TODAY'S FREE FLY STORIES

ESRX

Express Scripts

$61.00

-1.01 (-1.63%)

14:25
09/20/17
09/20
14:25
09/20/17
14:25
Options
Express Scripts call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 25

    Oct

14:25
09/20/17
09/20
14:25
09/20/17
14:25
General news
FX Action: The dollar rose, then fell, then rose again »

FX Action: The dollar…

14:25
09/20/17
09/20
14:25
09/20/17
14:25
Conference/Events
Federal Reserve Chairperson Yellen holds a press conference »

Following a quarterly…

CVS

CVS Health

$81.68

-1.42 (-1.71%)

, WBA

Walgreens Boots Alliance

$81.21

-1.39 (-1.68%)

14:20
09/20/17
09/20
14:20
09/20/17
14:20
Hot Stocks
Pharmacies drop after Leerink says Amazon talking to PBMs »

After speaking with…

CVS

CVS Health

$81.68

-1.42 (-1.71%)

WBA

Walgreens Boots Alliance

$81.21

-1.39 (-1.68%)

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

ESRX

Express Scripts

$61.00

-1.01 (-1.63%)

ABC

AmerisourceBergen

$78.74

-0.54 (-0.68%)

CAH

Cardinal Health

$66.44

0.179 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 17

    Oct

  • 22

    Oct

  • 25

    Oct

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

14:20
09/20/17
09/20
14:20
09/20/17
14:20
Recommendations
Alnylam analyst commentary  »

Alnylam price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

14:20
09/20/17
09/20
14:20
09/20/17
14:20
General news
Treasury Action: yields knee-jerked higher »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

14:17
09/20/17
09/20
14:17
09/20/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
09/20/17
09/20
14:16
09/20/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWKS

Skyworks

$107.93

0.44 (0.41%)

14:15
09/20/17
09/20
14:15
09/20/17
14:15
Options
Skyworks put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

14:15
09/20/17
09/20
14:15
09/20/17
14:15
General news
FOMC announced balance sheet runoff in October and left rates unchanged »

FOMC announced balance…

14:15
09/20/17
09/20
14:15
09/20/17
14:15
General news
Breaking General news story  »

Fed Chair Press…

SPY

SPDR S&P 500 ETF Trust

$249.89

-0.08 (-0.03%)

, SPX

S&P 500

14:13
09/20/17
09/20
14:13
09/20/17
14:13
Technical Analysis
Technical View: S&P 500 slips below the pivot low »

The S&P 500 (SPX) is…

SPY

SPDR S&P 500 ETF Trust

$249.89

-0.08 (-0.03%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZRX

PhaseRx

$0.78

0.055 (7.64%)

14:11
09/20/17
09/20
14:11
09/20/17
14:11
Hot Stocks
PhaseRx confirms receipt of FDA orphan drug designation for PRX-ASL »

PhaseRx announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$49.34

0.24 (0.49%)

14:10
09/20/17
09/20
14:10
09/20/17
14:10
Hot Stocks
Sanofi reports 'potential breakthrough' in preclinical work on HIV antibodies »

Researchers working…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SPX

S&P 500

14:06
09/20/17
09/20
14:06
09/20/17
14:06
General news
Fed details plans to being reducing balance sheet »

The Federal Reserve said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$14.06

0.29 (2.11%)

14:05
09/20/17
09/20
14:05
09/20/17
14:05
Options
Valeant call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

SPY

SPDR S&P 500 ETF Trust

$249.87

-0.1 (-0.04%)

, SPX

S&P 500

14:04
09/20/17
09/20
14:04
09/20/17
14:04
General news
Federal Reserve maintains median projection for year-end funds rate at 1.4% »

The Fed's "dot…

SPY

SPDR S&P 500 ETF Trust

$249.87

-0.1 (-0.04%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

14:02
09/20/17
09/20
14:02
09/20/17
14:02
General news
Fed says economic activity rising moderately this year »

The Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$68.25

-0.24 (-0.35%)

, SYMC

Symantec

$34.16

0.39 (1.15%)

14:02
09/20/17
09/20
14:02
09/20/17
14:02
Periodicals
Breaking Periodicals news story on Splunk, Symantec »

Symantec 'play'…

SPLK

Splunk

$68.25

-0.24 (-0.35%)

SYMC

Symantec

$34.16

0.39 (1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SPX

S&P 500

14:01
09/20/17
09/20
14:01
09/20/17
14:01
General news
Fed plans to initiate balance sheet normalization in October »

The Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:01
09/20/17
09/20
14:01
09/20/17
14:01
General news
FOMC Meeting Announcement Federal Funds Rate data reported »

FOMC Meeting Announcement…

14:00
09/20/17
09/20
14:00
09/20/17
14:00
General news
Breaking General news story  »

Federal Reserve leaves…

RNVA

Rennova Health

$0.22

-0.0021 (-0.93%)

13:55
09/20/17
09/20
13:55
09/20/17
13:55
Conference/Events
Rennova Health to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MLCO

Melco Resorts & Entertainment

$23.78

0.77 (3.35%)

13:50
09/20/17
09/20
13:50
09/20/17
13:50
Options
Bullish option play opened in Melco Resorts as shares tick to 52-week highs »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MOH

Molina Healthcare

$62.33

0.21 (0.34%)

, UNH

UnitedHealth

$195.34

0.69 (0.35%)

13:48
09/20/17
09/20
13:48
09/20/17
13:48
Periodicals
McConnell intends to consider healthcare bill in Senate next week, WSJ says »

A spokesman for Senate…

MOH

Molina Healthcare

$62.33

0.21 (0.34%)

UNH

UnitedHealth

$195.34

0.69 (0.35%)

CNC

Centene

$90.10

0.32 (0.36%)

WCG

WellCare

$166.10

-2.065 (-1.23%)

CI

Cigna

$181.44

-0.07 (-0.04%)

ANTM

Anthem

$181.90

0.46 (0.25%)

HNT

Health Net

HUM

Humana

$238.58

-1.46 (-0.61%)

AET

Aetna

$154.56

-1.48 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.